2021
Variable Clinical Presentation of Children with Hereditary Hypophosphatemic Rickets with Hypercalciuria: A Case Series and Review of the Literature
Christensen S, Tebben P, Sas D, Creo A. Variable Clinical Presentation of Children with Hereditary Hypophosphatemic Rickets with Hypercalciuria: A Case Series and Review of the Literature. Hormone Research In Paediatrics 2021, 94: 374-389. PMID: 34666334, DOI: 10.1159/000520299.Peer-Reviewed Original ResearchConceptsHereditary hypophosphatemic ricketsRenal symptomsPhosphate wastingHypophosphatemic ricketsVariable clinical presentationRenal phosphate wastingPhenotype-genotype correlationSLC34A3 mutationsUrine phosphateBone symptomsCase seriesMineralization defectRare conditionSLC34A3 variantsSerum phosphorusHHRHAccurate diagnosisUrinary stonesPatientsCombined boneHypercalciuriaLiterature reviewSymptomsSLC34A3Systematic literature reviewVariable Clinical Presentation of Children With Hereditary Hypophosphatemic Rickets With Hypercalciuria: A Case Series
Christensen S, Tebben P, Sas D, Creo A. Variable Clinical Presentation of Children With Hereditary Hypophosphatemic Rickets With Hypercalciuria: A Case Series. Journal Of The Endocrine Society 2021, 5: a708-a708. PMCID: PMC8090272, DOI: 10.1210/jendso/bvab048.1442.Peer-Reviewed Original ResearchYear old maleYear old femaleHereditary hypophosphatemic ricketsHypophosphatemic ricketsDihydroxyvitamin DSerum phosphorusPhosphate wastingVitamin DElevated 1,25-dihydroxyvitamin DRecurrent urinary stonesLower extremity painVariable clinical presentationLow serum phosphorusPatellofemoral pain syndromePhenotype-genotype correlationProximal renal tubular cellsRenal tubular cellsSLC34A3 geneRenal ultrasoundUrine phosphorusExtremity painPain syndromePresenting symptomsUrine phosphateBone symptomsBasal Ganglia Calcification Is Associated With Local and Systemic Metabolic Mechanisms in Adult Hypoparathyroidism
Zavatta G, Tebben P, McCollough C, Yu L, Vrieze T, Clarke B. Basal Ganglia Calcification Is Associated With Local and Systemic Metabolic Mechanisms in Adult Hypoparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2021, 106: 1900-1917. PMID: 33788935, DOI: 10.1210/clinem/dgab162.Peer-Reviewed Original ResearchConceptsLow serum calciumBasal ganglia calcificationSerum calciumChronic hypoparathyroidismNonsurgical patientsSerum phosphorusAssociated with lower serum calciumComputed tomographyDecreased serum parathyroid hormoneRetrospective review of medical recordsReview of medical recordsSerum parathyroid hormoneAssociated with soft tissue calcificationSex-matched controlsAssociated with greater volumeDuration of treatmentCase-control studyDistribution of calcificationSoft tissue calcificationIncreased serum phosphorusCalcium/phosphate ratioCT headRetrospective reviewParathyroid hormoneImaging findings
2020
Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate Supplementation
Eswarakumar AS, S. N, Ward LM, Backeljauw P, Wasserman H, Weber DR, DiMeglio LA, Imel EA, Gagne J, Cody D, Zimakas P, Topor LS, Agrawal S, Calabria A, Tebben P, Faircloth RS, Gordon R, Casey L, Carpenter TO. Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate Supplementation. Clinical Pediatrics 2020, 59: 1080-1085. PMID: 32666808, DOI: 10.1177/0009922820941097.Peer-Reviewed Original ResearchConceptsElemental formula useBone diseaseFormula useHypophosphatemic bone diseaseTerm Follow-upLong-term outcomesSerum phosphorus concentrationSerum alkaline phosphatase activitySerum alkaline phosphataseSeverity/durationTime of correctionChart reviewSerum phosphorusDisease AssociatedFollow-upPhosphate supplementationExtent of recoveryDiseaseDiagnosisFormula changesRadiology reportsSupplementationAlkaline phosphataseAlkaline phosphatase activityReport
2005
Elevated fibroblast growth factor 23 in women with malignant ovarian tumors.
Tebben P, Kalli K, Cliby W, Hartmann L, Grande J, Singh R, Kumar R. Elevated fibroblast growth factor 23 in women with malignant ovarian tumors. Mayo Clinic Proceedings 2005, 80: 745-51. PMID: 15948297, DOI: 10.1016/s0025-6196(11)61528-0.Peer-Reviewed Original ResearchConceptsAdvanced-stage ovarian cancerEarly-stage ovarian cancerOvarian cancerFGF23 concentrationsPlasma FGF23 concentrationCFGF23 concentrationsSerum iFGF23Ovarian tumorsHealthy womenMalignant ovarian cancer cellsMalignant ovarian tumorsBenign ovarian tumorsAdvanced-stage diseaseAdvanced-stage tumorsFibroblast growth factor 23Elevated fibroblast growth factorOvarian cancer cellsSerum phosphate concentrationStage of diseaseSerum FGF23 concentrationsOvarian massBenign diseaseSerum phosphorusBenign massesMayo ClinicElevated Fibroblast Growth Factor 23 in Women With Malignant Ovarian Tumors
Tebben P, Kalli K, Cliby W, Hartmann L, Grande J, Singh R, Kumar R. Elevated Fibroblast Growth Factor 23 in Women With Malignant Ovarian Tumors. Mayo Clinic Proceedings 2005, 80: 745-751. DOI: 10.4065/80.6.745.Peer-Reviewed Original ResearchAdvanced-stage ovarian cancerEarly-stage ovarian cancerOvarian cancerFibroblast growth factor 23FGF23 concentrationsPlasma FGF23 concentrationCFGF23 concentrationsSerum iFGF23Ovarian tumorsHealthy womenAdvanced-stage epithelial ovarian cancerMalignant ovarian cancer cellsElevated fibroblast growth factor 23Benign ovarian tumorsMalignant ovarian tumorsAdvanced-stage diseaseEpithelial ovarian cancerAdvanced-stage tumorsOvarian cancer cellsStage of diseaseSerum phosphate concentrationSerum FGF23 concentrationsOvarian massBenign diseaseSerum phosphorus
2004
Fibroblast Growth Factor 23, Parathyroid Hormone, and 1α,25-Dihydroxyvitamin D in Surgically Treated Primary Hyperparathyroidism
Tebben P, Singh R, Clarke B, Kumar R. Fibroblast Growth Factor 23, Parathyroid Hormone, and 1α,25-Dihydroxyvitamin D in Surgically Treated Primary Hyperparathyroidism. Mayo Clinic Proceedings 2004, 79: 1508-1513. PMID: 15595334, DOI: 10.4065/79.12.1508.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersDihydroxycholecalciferolsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFollow-Up StudiesHumansHyperparathyroidismMaleMiddle AgedParathyroid GlandsParathyroid HormoneParathyroidectomyPostoperative CarePreoperative CareProbabilityProspective StudiesSampling StudiesSensitivity and SpecificitySeverity of Illness IndexStatistics, NonparametricTreatment OutcomeConceptsBone-specific alkaline phosphataseBone-specific alkaline phosphatase concentrationsFibroblast growth factor 23Primary hyperparathyroidismParathyroid hormoneSerum phosphorus concentrationFGF23 concentrationsSerum calciumSurgically treated primary hyperparathyroidismElevated serum calciumLow-normal rangeParathyroid hormone concentrationsAdult patientsPreoperative stateSerum phosphorusPostoperative stateHyperparathyroidismHealthy controlsFibroblast growth factorPatientsFGF23Growth factorSurgerySerumPhosphorus homeostasis